Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 13/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016567 | 0.86 | ITGAV (0.44) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL6016500 | 0.85 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL275460 | 0.82 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL8350656 | 0.81 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL275631 | 0.81 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL6016358 | 0.79 | ITGB3 (0.50) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL277546 | 0.77 | ITGAV (0.62) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL5584350 | 0.77 | ITGAV (0.62) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL27474218 | 0.77 | KMT2A (0.39) | HTR2CHRH4 | |
| SCHEMBL4640715 | 0.77 | KMT2A (0.39) | HTR2CHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210348-B9 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1210348-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-07 | — | — | US | disclosed |
| US-6743800-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND INHIBITORS OF CELL ADHESION; OSTEOPOROSIS, ANGIOGENESIS INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | VCAM1, ADGRF1, ADGRE5 | ITGAV 181/4885ITGB6 55/4885ITGB3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.